Nicholas Naclerio

Jun 09, 2015

Twist Bioscience announced that Nicholas Naclerio, Illumina's senior VP of corporate development and general manager of enterprise informatics, will join its board. Before his current position at Illumina, he was its SVP of corporate and venture development. He previously was the co-founder and chairman of Quanterix.

More Like This

Feb 22, 2018

Clive Brown

Clive Brown's appointment as director of Oxford Nanopore Technologies ended on Jan. 25, the company said in a filing this week. He remains the firm's chief technology officer.

Feb 21, 2018

Anthony Mattacchione, Gerald Herman

Bruker announced today that its Anthony Mattacchione will resign as chief financial officer and senior VP, effective Mar. 16, 2018. Mattacchione has accepted a position as CFO of Albany Molecular Research, commencing in Apr. 2018. VP and corporate controller Gerald N. Herman will serve as Bruker's princapl accounting officer, effective immediately. Herman joined the firm in 2016 as VP-corporate controller. Prior to that, he served as corporate VP-clinical operations of Parexel international from 2014 to Feb. 2016, and before that, corporate VP of Parexel from 2008 to 2013. Before that, Herman served as VP-corporate controller of Presstek. 

Feb 20, 2018

Robert Hugin

Robert Hugin has resigned as a director at Danaher, following his decision to run for the US Senate representing New Jersey. He will run as a Republican against Sen. Robert Menendez, a Democrat. According to Politco, Hugin is a supporter of President Donald Trump. He was previously the executive chairman of Celgene before retiring from that position in January, and he was CEO of the company from June 2010 to March 2016. 

Feb 16, 2018

John Goetz

John Goetz, the executive vice president and chief operating officer of Bio-Rad Laboratories, will retire and resign from his position effective March 30, 2018, but will remain available for consultation after his employment ends if a successor has not yet been named. Goetz has been with Bio-Rad for more than 40 years and was named COO in 2014. 

Feb 16, 2018

Shawn Clairmont

Codexis has appointed Shawn Clairmont senior director of molecular diagnostics. She will be responsible for commercial activities related to the firm's molecular diagnostics enzyme product line in development. Clairmont previously served as chief operating officer of BRIDGenomics. She was with Qiagen for eight years, most recently in the global advanced molecular pathology team as director of sales in America, and was also technical marketing representative and account manager at BioArray Solutions (now part of Immucor).

Feb 13, 2018

Michael Pellini

Adaptive Biotechnologies announced that former Foundation Medicine CEO Michael Pellini has joined its board. Pellini is currently chairman of Foundation Medicine's board, and is a managing partner of life science venture capital firm Section 32. He previously was president and chief operating officer of Clarient, which was acquired by GE Healthcare in 2010. He currently also serves on the boards of Tango Therapeutics, Singular Genomics, the Personalized Medicine Coalition, and the Mission Hospital Foundation. 

Feb 09, 2018

Eutillio Buccilli, Paul Kasian

Genetic Technologies, a Melbourne, Australia-based molecular diagnostics company, said this week that Eutillio Buccilli will step down as CEO. Buccilli joined the company in June 2014 as CFO and was appointed CEO in February 2015. Paul Kasian has been appointed interim CEO while the company undertakes an executive search for a permanent CEO.

Feb 07, 2018

Alberto Gutierrez

Alberto Gutierrez has joined NDA Partners as an expert consultant. The company provides consulting services in product development and regulation of medical products. Gutierrez is the former director, Office of In Vitro Diagnostics and Radiological Health, FDA Center for Devices and Radiological Health. He spent 25 years at the agency before leaving last September

Feb 05, 2018

Panna Sharma

Cancer Genetics announced that its CEO Panna Sharma will be stepping down as president, director, and CEO of the firm. The company’s board has appointed current COO John Roberts as the interim CEO. Sharma will provide consulting services during the transition period. 

Feb 02, 2018

Matthew McGrew, Daniel Comas

Danaher announced Matthew McGrew will become the firm's CFO, effective Jan. 1, 2019. He will replace Daniel Comas, who will continue as an executive vice president and a member of the Office of the Chief Executive as he begins a gradual transition to retirement. McGrew joined Danaher in 2004 as director M&A Finance. He currently is Group CFO of Danaher's Diagnostics and Dental platforms. Comas has been with Danaher since 1991 and became its CFO in 2005. 

Feb 01, 2018

Jonathan Sheldon

Qiagen has hired Jonathan Sheldon as senior vice president in charge of the company's bioinformatics business, to fill the vacancy created when Laura Furmanski left late last year. Sheldon, who also joins Qiagen's executive committee, most recently had been in charge of health sciences at Oracle. He previously started and directed the bioinformatics group at Roche (UK) Pharmaceuticals.

Jan 30, 2018

Mike Harkins, Katherine Atkinson

Edico Genome has named Mike Harkins as vice president of sales and Katherine Atkinson as VP of business development. Together, they will seek to expand the global market for the DRAGEN bio IT platform, the company said. Harkins previously led bioproduction sales at Thermo Fisher Scientific, while Atkinson most recently was commercial director of global channel partners for Illumina.

Jan 25, 2018

David Atkins

David Atkins has been named CEO of Congenica, a Cambridge, England-based maker of clinical genomics interpretation software. Atkins will lead Congenica as it looks to expand to the US and Asia, the company said. He previously served as CEO of Synevo, a chain of clinical diagnostic laboratories in Germany and Eastern Europe. With the hiring of Atkins, interim CEO Nick Lench resumes his full-time duties as chief operating officer. Cofounder and former CEO Tom Weaver remains on the Congenica board.

Jan 25, 2018

Greg Dale

LexaGene announced today that it has appointed Greg Dale as VP of product development and manufacturing. Dale previously served as VP of product development, manufacturing, and quality at Emulate. Prior to Emulate, Dale served as general manager and senior director of NGS engineering at Qiagen. 

Jan 24, 2018

Nalini Murdter

JSR Life Sciences has appointed Nalini Murdter as president and CEO of MBL International (MBLI), a JSR subdivision that provides products for life sciences research and clinical diagnostics, specializing in reagents and assays for detecting biomarkers and analyzing disease pathways. Murdter previously served as vice president of commercial operations and business development at MBLI, and managing director of the diagnostics and research products division at JSR. She was previously chief business offices a NanoString Technologies, and held several senior management positions in business development, strategy, and marketing at Agilent Technologies.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.